Back to top
more

Viatris (VTRS)

(Delayed Data from NSDQ)

$16.32 USD

16.32
6,494,467

+0.20 (1.24%)

Updated Aug 21, 2026 04:00 PM ET

After-Market: $16.34 +0.02 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 247)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Viatris to Report Q3 Earnings: Is a Beat in the Cards for the Stock?

by Zacks Equity Research

VTRS is set to report Q3 results, with brand strength offsetting generics pressure and a model hinting at an earnings beat.

Ahan Chakraborty headshot

CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?

by Ahan Chakraborty

CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.

Zacks Equity Research

Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is Viatris (VTRS) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan

by Zacks Equity Research

VTRS acquires Aculys Pharma to boost its CNS portfolio in Japan, gaining rights to pitolisant and Spydia for narcolepsy and seizure management, respectively.

Zacks Equity Research

Zacks Investment Ideas feature highlights: Church & Dwight, Eli Lilly and Viatris

by Zacks Equity Research

CEOs at Church & Dwight, Eli Lilly, and Viatris are buying shares after stock pullbacks, signaling insider confidence.

Derek Lewis headshot

Insider Watch: 3 CEOs Buying the Dip

by Derek Lewis

Large-cap stocks CHD, LLY, and VTRS have seen their respective CEOs make purchases over the last month. What do they see?

Zacks Equity Research

Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.

Zacks Equity Research

Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.